Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX Other stock markets 17:21:45 01/05/2024 BST			5-day change	1st Jan Change
26.52 ^USD	+3.49%		+5.67%	-34.48%

04-07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
03-20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	03-20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	03-19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	03-11	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	03-04	MT
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	02-23	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	02-23	MT
HC Wainwright Raises BridgeBio Pharma Price Target to $47 From $22, Maintains Buy Rating	01-29	MT
JPMorgan Adjusts BridgeBio Pharma Price Target to $35 From $38, Maintains Overweight Rating	11-24	MT
Citigroup Starts BridgeBio Pharma With Buy Rating, $42 Price Target	11-07	MT
BridgeBio Pharma Says Heart Disease Drug Showed 81% Survival Rate in Phase 3 Study	28/08/23	MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $38 From $42, Maintains Overweight Rating	17/08/23	MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Buy Rating	14/08/23	MT
Raymond James Raises Price Target on BridgeBio Pharma to $46 From $29, Maintains Outperform Rating	18/07/23	MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	18/07/23	MT
Jefferies Downgrades BridgeBio Pharma to Hold From Buy, Adjusts Price Target to $33 From $24	18/07/23	MT
Mizuho Hikes Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating	18/07/23	MT
In wait-and-see mode before Tesla and Netflix	17/07/23
Mizuho Securities Adjusts BridgeBio Pharma Price Target to $29 From $23, Maintains Buy Rating	08/05/23	MT
Evercore ISI Starts BridgeBio Pharma at Outperform With $40 Price Target	19/04/23	MT
SVB Securities Raises Price Target on BridgeBio Pharma to $27 From $25, Keeps Outperform Rating	13/04/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Analyst Reco.

Filters